Assessment Status |
Full HTA submission received from Applicant |
HTA ID |
22036 |
Drug |
Atezolizumab |
Brand |
Tecentriq® |
Indication |
As an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC. |
Rapid review commissioned |
18/05/2022 |
Rapid review completed |
02/06/2022 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard-of-care. |
Full pharmacoeconomic assessment commissioned by HSE |
01/07/2022 |
Pre-submission consultation with Applicant |
04/10/2022 |
Full submission received from Applicant |
02/12/2022 |